Table 2.
Characteristics of patients who initially presented with GP and acquired PV phenotype (n = 21) compared to patients with nontransformed GP phenotype (n = 99)
| Characteristic | PV (n = 21), N (%) | GP (n = 99), N (%) | OR | CI | p Value |
|---|---|---|---|---|---|
| Follow-up, years, mean (SD) | 6.2 (2.6) | 6.1 (3.2) | 1.00 | 0.86–1.17 | 0.07 |
| Age at first event, years, mean (SD) | 23.1 (14.5) | 29.8 (15.3) | 0.96 | 0.93–1.00 | 0.36 |
| Female gender (%) | 11 (52.4) | 59 (59.6) | 0.74 | 0.29–1.92 | 0.54 |
| Family history of psoriasis | 11 (52.4) | 32 (32.7) | 2.26 | 0.87–5.89 | 0.08 |
| Missing data | N = 1 | N = 2 | |||
| GP episodes, n (%) | |||||
| 1 | 4 (19.0) | 45 (45.5) | 0.28 | 0.08–0.90 | 0.02 |
| 2–3 | 6 (28.3) | 26 (26.3) | 1.12 | 0.39–3.20 | 0.82 |
| Over 3 | 11 (52.4) | 28 (28.3) | 2.78 | 1.06–7.29 | 0.03 |
| Area involved | |||||
| Trunk | 18 (94.7) | 86 (92.5) | 1.46 | 0.17–12.65 | 0.72 |
| Limbs | 18 (94.7) | 89 (95.7) | 0.80 | 0.08–7.66 | 0.85 |
| Head | 8 (42.1) | 44 (47.3) | 0.81 | 0.29–2.19 | 0.67 |
| Diffuse | 8 (42.1) | 42 (45.2) | 0.88 | 0.32–2.39 | 0.80 |
| Missing data | N = 2 | N = 6 | |||
| URTI anticipating GP flare | |||||
| At first GP episode | 10 (47.6) | 66 (66.7) | 0.45 | 0.17–1.17 | 0.10 |
| At some GP episodes | 5 (23.8) | 14 (14.1) | 0.55 | 0.21–1.45 | 0.27 |
| With confirmed streptococcal infectiona | 4 (66.7) | 19 (48.7) | 2.10 | 0.34–12.86 | 0.41 |
| Missing data | 17 | 60 | |||
| Hand and foot involvement | |||||
| At first GP episode | 6 (35.3) | 14 (18.9) | 2.33 | 0.73–7.40 | 0.14 |
| At some GP episodes | 7 (41.2) | 19 (25.7) | 2.02 | 0.67–6.07 | 0.20 |
| Missing data | N = 5 | N = 24 | |||
| Scalp involvement | |||||
| At first episode | 12 (57.1) | 44 (44.9) | 1.63 | 0.63–4.23 | 0.30 |
| At some GP episodes | 17 (81.0) | 49 (50.0) | 4.25 | 1.33–13.54 | 0.01 |
| Missing data | N = 0 | N = 1 | |||
| Comorbidity, (%) | |||||
| Arthralgia/Arthritis | 5 (23.8) | 13 (13.1) | 2.06 | 0.64–6.60 | 0.21 |
| Hypertension | 1 (4.8) | 7 (7.1) | 0.65 | 0.07–5.64 | 0.70 |
| Hyperlipidemia | 1 (4.8) | 8 (8.1) | 0.56 | 0.06–4.80 | 0.60 |
| Diabetes | 1 (4.8) | 4 (4.0) | 1.18 | 0.12–11.19 | 0.88 |
| Obesity | 1 (4.8) | 10 (10.4) | 0.44 | 0.05–3.67 | 0.44 |
| Most potent treatment at first GP episode | |||||
| Topical | 2 (10.0) | 12 (2.5) | 0.77 | 0.16–3.78 | 0.75 |
| Phototherapy | 14 (70.0) | 80 (83.3) | 0.46 | 0.15–1.39 | 0.16 |
| Oral agentsb | 4 (20.0) | 4 (4.2) | 5.75 | 1.30–25.36 | 0.01 |
| Biological | 0 (0) | 0 (0) | |||
| Most potent treatment along disease course | |||||
| Topical | 3 (14.3) | 12 (12.1) | 1.20 | 0.30–4.72 | 0.79 |
| Phototherapy | 9 (42.9) | 76 (76.8) | 0.22 | 0.08–0.60 | 0.002 |
| Oral agents b | 5 (23.8) | 8 (8.1) | 3.55 | 1.03–12.25 | 0.03 |
| Biological | 4 (19.0) | 3 (3.0) | 7.52 | 1.54–36.6 | 0.004 |
CI, confidence interval; GP, guttate psoriasis; OR, odds ratio; URTI, upper respiratory tract infection; SD, standard deviation; ASLO, antistreptolysin O.
a
Throat culture positive for group A β-hemolytic Streptococcus or positive ASLO titer (>200 U/mL, taken up to 5 weeks from the onset of symptoms).
b
Acitretin, immunosuppressants, and phosphodiesterase 4 inhibitors.